Zkusit zdarma
Roivant Sciences Ltd.

Roivant Sciences Ltd.

ROIV
Cena:
$ 29.96
-0.92 (-2.98%)
Valuace
70
Růst
10
Zdraví
68
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

18:20 20-05-2026

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript...

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences Q4 Earnings Call Highlights

10:08 20-05-2026

Roivant Sciences NASDAQ: ROIV executives used the company's fourth-quarter earnings call to highligh...

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

9:15 20-05-2026

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.36 per share versus the Zacks Cons...

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

7:00 20-05-2026

BASEL, Switzerland and LONDON and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) ...

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why

13:01 19-05-2026

Montes Archimedes Acquisition (ROIV) might move higher on growing optimism about its earnings prospe...

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

16:50 13-05-2026

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcrip...

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

16:05 11-05-2026

BASEL, Switzerland and LONDON and NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Brokerages

4:27 15-04-2026

Roivant Sciences Ltd. (NASDAQ: ROIV - Get Free Report) has earned a consensus recommendation of "Mod...

Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV

Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV

4:20 12-04-2026

Elevate Capital Advisors LLC cut its stake in shares of Roivant Sciences Ltd. (NASDAQ: ROIV) by 31.8...

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should Know

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should Know

13:00 10-04-2026

Montes Archimedes Acquisition (ROIV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing ...

Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV

Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV

4:43 06-04-2026

Capricorn Fund Managers Ltd raised its stake in Roivant Sciences Ltd. (NASDAQ: ROIV) by 124.4% durin...

Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint

Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint

1:05 04-04-2026

Roivant Sciences (NASDAQ: ROIV) outlined plans to expand development of its JAK1/TYK2 inhibitor brep...

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript

16:32 02-04-2026

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data ...

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

5:00 02-04-2026

Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irrev...

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

15:00 28-03-2026

DURHAM, N.C., March 28, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics, a clinical-stage biotechnolo...

105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY

105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY

3:36 17-03-2026

Bamco Inc. NY acquired a new stake in Roivant Sciences Ltd. (NASDAQ: ROIV) during the undefined quar...

Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript

14:12 11-03-2026

Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript...

Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript

Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript

5:22 04-03-2026

Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Paten...

Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

13:32 03-03-2026

Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript...

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

7:00 03-03-2026

FDA assigns PDUFA target action date in the third quarter of calendar year 2026 with launch expected...

close

PULMOVANT ANNOUNCES COMPLETION OF ENROLLMENT IN THE PHASE 2 PHOCUS STUDY OF MOSLICIGUAT IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD)

06-02-2026
WALTHAM, MASS., FEB. 06, 2026 (GLOBE NEWSWIRE) -- PULMOVANT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ...
Více zde

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2025, AND PROVIDE BUSINESS UPDATE ON FRIDAY, FEBRUARY 6, 2026

23-01-2026
BASEL, SWITZERLAND AND LONDON AND NEW YORK, JAN. 23, 2026 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ROIVANT HIGHLIGHTS CONTINUED PIPELINE PROGRESS AND OUTLOOK FOR COMPANY'S NEXT PHASE OF GROWTH AT 2025 INVESTOR DAY

11-12-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, DEC. 11, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ROIVANT REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDES BUSINESS UPDATE

10-11-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, NOV. 10, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDE BUSINESS UPDATE ON MONDAY, NOVEMBER 10, 2025

27-10-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, OCT. 27, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ROIVANT AND PRIOVANT ANNOUNCE POSITIVE PHASE 3 VALOR STUDY RESULTS FOR BREPOCITINIB IN 52-WEEK PLACEBO-CONTROLLED TRIAL IN DERMATOMYOSITIS (DM)

17-09-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK AND DURHAM, N.C., SEPT. 17, 2025 (GLOBE NEWSWIRE) -- RO...
Více zde

ROIVANT NAMED ON FORTUNE MEDIA AND GREAT PLACE TO WORK'S 2025 BEST WORKPLACES IN BIOPHARMA LIST

11-09-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, SEPT. 11, 2025 (GLOBE NEWSWIRE) -- GREAT PLACE TO WORK®...
Více zde

PULMOVANT RECEIVES ORPHAN DRUG DESIGNATION IN JAPAN FOR MOSLICIGUAT FOR THE TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (PH-ILD)

04-09-2025
ORPHAN DRUG DESIGNATION FROM JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE PROVIDES KEY REGULATORY ...
Více zde

ROIVANT UNVEILS DURABILITY AND TREATMENT-FREE SIX-MONTH REMISSION DATA WITH POTENTIAL TO CHANGE TREATMENT PARADIGM FOR UNCONTROLLED GRAVES' DISEASE PATIENTS

03-09-2025
NEW YORK, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

ROIVANT REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDES BUSINESS UPDATE

11-08-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, AUG. 11, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2025, AND PROVIDE BUSINESS UPDATE ON MONDAY, AUGUST 11, 2025

28-07-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, JULY 28, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

PULMOVANT ANNOUNCES PUBLICATION OF PHARMACOKINETICS AND LUNG DEPOSITION DATA FOR INHALED MOSLICIGUAT IN CLINICAL PHARMACOKINETICS

16-06-2025
THREE PHASE 1 STUDIES SUPPORT ONCE-DAILY INHALED ADMINISTRATION OF MOSLICIGUAT WITH NO EVIDENCE OF S...
Více zde

ROIVANT AND PRIOVANT TO HOST INVESTOR VIDEO CONFERENCE AT 1:00 PM ET ON TUESDAY, JUNE 17 ON BREPOCITINIB AND THE UNMET MEDICAL NEED IN DERMATOMYOSITIS

09-06-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, JUNE 09, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ROIVANT REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025, AND PROVIDES BUSINESS UPDATE

29-05-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 29, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) ...
Více zde

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2025 AND PROVIDE BUSINESS UPDATE ON THURSDAY, MAY 29, 2025

15-05-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 15, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) ...
Více zde

IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJÖGREN'S DISEASE (SJD) AND CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) FOR IMVT-1402

21-04-2025
NEW YORK, APRIL 21, 2025 (GLOBE NEWSWIRE) --  IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE ...
Více zde

ROIVANT ANNOUNCES POSITIVE RESULTS FOR BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) STUDIES

19-03-2025
NEW YORK, MARCH 19, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

ROIVANT TO HOST INVESTOR WEBCAST AT 8:00 AM ET ON WEDNESDAY, MARCH 19 TO REVIEW RESULTS FROM BATOCLIMAB MYASTHENIA GRAVIS (MG) AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) PROGRAMS

18-03-2025
NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

GENEVANT SCIENCES AND ARBUTUS BIOPHARMA INITIATE INTERNATIONAL PATENT INFRINGEMENT ENFORCEMENT ACTIONS AGAINST MODERNA

03-03-2025
BASEL, SWITZERLAND AND VANCOUVER, B.C. AND WARMINSTER, PA., MARCH 03, 2025 (GLOBE NEWSWIRE) -- GENEV...
Více zde

ROIVANT REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024, AND PROVIDES BUSINESS UPDATE

10-02-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, FEB. 10, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ZEST HEALTH ANNOUNCES $13M IN FUNDING TO CURB UNNECESSARY PHARMACEUTICAL SPEND THROUGH HIGH-TOUCH CARE

03-02-2025
ZEST IS INITIALLY FOCUSED ON TREATING THE MILLIONS OF AMERICANS WITH INFLAMMATORY SKIN DISEASES WHO ...
Více zde

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED DECEMBER 31, 2024 AND PROVIDE BUSINESS UPDATE ON MONDAY, FEBRUARY 10, 2025

29-01-2025
BASEL, SWITZERLAND AND LONDON AND NEW YORK, JAN. 29, 2025 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024 AND PROVIDE BUSINESS UPDATE ON TUESDAY, NOVEMBER 12, 2024

29-10-2024
BASEL, SWITZERLAND AND LONDON AND NEW YORK, OCT. 29, 2024 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV)...
Více zde

ORGANON COMPLETES ACQUISITION OF DERMAVANT, INCLUDING INNOVATIVE DERMATOLOGIC THERAPY, VTAMA® (TAPINAROF) CREAM, 1%

28-10-2024
THE ACQUISITION EXPANDS ORGANON'S DERMATOLOGY CAPABILITIES WITH A NONBIOLOGIC, NON-STEROIDAL TOPICAL...
Více zde

ORGANON TO ACQUIRE DERMAVANT INCLUDING ITS INNOVATIVE DERMATOLOGIC THERAPY, VTAMA® (TAPINAROF) CREAM, 1%

18-09-2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--ORGANON ENTERS AGREEMENT TO ACQUIRE DERMAVANT INCLUDING INNOVATI...
Více zde

ROIVANT UNVEILS NEW PIPELINE PROGRAM MOSLICIGUAT, A POTENTIAL FIRST-IN-CLASS AND BEST-IN-CATEGORY INHALED ONCE-DAILY SOLUBLE GUANYLATE CYCLASE (SGC) ACTIVATOR

10-09-2024
BASEL, SWITZERLAND AND LONDON AND NEW YORK, SEPT. 10, 2024 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV...
Více zde

ROIVANT PROVIDES UPDATE ON GRAVES' DISEASE DEVELOPMENT PROGRAM

09-09-2024
NEW YORK, SEPT. 09, 2024 (GLOBE NEWSWIRE) -- IMMUNOVANT, INC. (NASDAQ: IMVT), A CLINICAL-STAGE IMMUN...
Více zde

ROIVANT REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2024, AND PROVIDES BUSINESS UPDATE

30-05-2024
BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 30, 2024 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) ...
Více zde

ROIVANT TO REPORT FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR ENDED MARCH 31, 2024, AND PROVIDE BUSINESS UPDATE ON THURSDAY, MAY 30, 2024

16-05-2024
BASEL, SWITZERLAND AND LONDON AND NEW YORK, MAY 16, 2024 (GLOBE NEWSWIRE) -- ROIVANT (NASDAQ: ROIV) ...
Více zde

ROIVANT AND KINEVANT SCIENCES COMPLETE ENROLLMENT IN RESOLVE-LUNG, A PHASE 2 STUDY EVALUATING NAMILUMAB FOR CHRONIC PULMONARY SARCOIDOSIS

25-04-2024
BASEL, SWITZERLAND & LONDON & NEW YORK--(BUSINESS WIRE)--ROIVANT (NASDAQ: ROIV) AND KINEVANT SCIENCE...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2026-02-06 00:00:008-KStáhnout
2026-02-06 00:00:0010-QStáhnout
2025-12-11 00:00:008-KStáhnout
2025-11-10 00:00:008-KStáhnout
2025-11-10 00:00:0010-QStáhnout
2025-09-17 01:00:008-KStáhnout
2025-09-17 00:00:008-KStáhnout
2025-09-11 01:00:008-KStáhnout
2025-09-11 00:00:008-KStáhnout
2025-09-03 01:00:008-KStáhnout
2025-09-03 00:00:008-KStáhnout
2025-08-11 01:00:008-KStáhnout
2025-08-11 01:00:0010-QStáhnout
2025-08-11 00:00:008-KStáhnout
2025-08-11 00:00:0010-QStáhnout
2025-06-25 01:00:008-KStáhnout
2025-06-25 00:00:008-KStáhnout
2025-05-29 01:00:008-KStáhnout
2025-05-29 01:00:0010-KStáhnout
2025-05-29 00:00:008-KStáhnout
2025-05-29 00:00:0010-KStáhnout
2025-04-21 01:00:008-KStáhnout
2025-04-21 00:00:008-KStáhnout
2025-03-20 00:00:008-KStáhnout
2025-03-19 23:00:008-KStáhnout
2025-03-19 00:00:008-KStáhnout
2025-03-18 23:00:008-KStáhnout
2025-02-21 00:00:008-KStáhnout
2025-02-20 23:00:008-KStáhnout
2025-02-10 00:00:008-KStáhnout
2025-02-10 00:00:0010-QStáhnout
2025-02-09 23:00:008-KStáhnout
2025-02-09 23:00:0010-QStáhnout
2024-12-03 00:00:008-KStáhnout
2024-12-02 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-11 23:00:008-KStáhnout
2024-10-28 00:00:008-KStáhnout
2024-10-27 23:00:008-KStáhnout
2024-09-23 01:00:008-KStáhnout
2024-09-23 00:00:008-KStáhnout
2024-09-18 01:00:008-KStáhnout
2024-09-18 00:00:008-KStáhnout
2024-09-16 01:00:008-KStáhnout
2024-09-16 00:00:008-KStáhnout
2024-09-10 01:00:008-KStáhnout
2024-09-10 00:00:008-KStáhnout
2024-09-09 01:00:008-KStáhnout
2024-09-09 00:00:008-KStáhnout
2024-08-09 01:00:0010-QStáhnout
2024-08-09 00:00:0010-QStáhnout
2024-08-08 01:00:008-KStáhnout
2024-08-08 00:00:008-KStáhnout
2024-05-30 01:00:008-KStáhnout
2024-05-30 01:00:0010-KStáhnout
2024-05-30 00:00:008-KStáhnout
2024-05-30 00:00:0010-KStáhnout
2024-04-02 01:00:008-KStáhnout
2024-04-02 00:00:008-KStáhnout
2024-02-13 00:00:008-KStáhnout
2024-02-13 00:00:0010-QStáhnout
2024-02-12 23:00:008-KStáhnout
2024-02-12 23:00:0010-QStáhnout
2023-12-20 00:00:008-KStáhnout
2023-12-19 23:00:008-KStáhnout
2023-12-14 00:00:008-KStáhnout
2023-12-13 23:00:008-KStáhnout
2023-11-28 00:00:008-KStáhnout
2023-11-27 23:00:008-KStáhnout
2023-11-27 00:00:008-KStáhnout
2023-11-26 23:00:008-KStáhnout
2023-11-13 00:00:008-KStáhnout
2023-11-13 00:00:0010-QStáhnout
2023-11-12 23:00:008-KStáhnout
2023-11-12 23:00:0010-QStáhnout
2023-10-23 01:00:008-KStáhnout
2023-10-23 00:00:008-KStáhnout
2023-09-29 01:00:008-KStáhnout
2023-09-29 00:00:008-KStáhnout
2023-09-26 01:00:008-KStáhnout
2023-09-26 00:00:008-KStáhnout
2023-09-15 01:00:008-KStáhnout
2023-09-15 00:00:008-KStáhnout
2023-09-11 01:00:008-KStáhnout
2023-09-11 00:00:008-KStáhnout
2023-08-17 01:00:008-KStáhnout
2023-08-17 00:00:008-KStáhnout
2023-08-14 01:00:008-KStáhnout
2023-08-14 01:00:0010-QStáhnout
2023-08-14 00:00:008-KStáhnout
2023-08-14 00:00:0010-QStáhnout
2023-08-04 01:00:008-KStáhnout
2023-08-04 00:00:008-KStáhnout
2023-08-02 01:00:008-KStáhnout
2023-08-02 00:00:008-KStáhnout
2023-06-28 01:00:008-KStáhnout
2023-06-28 01:00:0010-KStáhnout
2023-06-28 00:00:008-KStáhnout
2023-06-28 00:00:0010-KStáhnout
2023-06-22 01:00:008-KStáhnout
2023-06-22 00:00:008-KStáhnout
2023-05-16 01:00:008-KStáhnout
2023-05-16 00:00:008-KStáhnout
2023-04-04 01:00:008-KStáhnout
2023-04-04 00:00:008-KStáhnout
2023-03-16 00:00:008-KStáhnout
2023-03-15 23:00:008-KStáhnout
2023-03-15 00:00:008-KStáhnout
2023-03-14 23:00:008-KStáhnout
2023-02-21 00:00:008-KStáhnout
2023-02-20 23:00:008-KStáhnout
2023-02-13 00:00:008-KStáhnout
2023-02-13 00:00:0010-QStáhnout
2023-02-12 23:00:008-KStáhnout
2023-02-12 23:00:0010-QStáhnout
2023-02-07 00:00:008-KStáhnout
2023-02-06 23:00:008-KStáhnout
2023-02-01 00:00:008-KStáhnout
2023-01-31 23:00:008-KStáhnout
2023-01-04 00:00:008-KStáhnout
2023-01-03 23:00:008-KStáhnout
2022-12-01 00:00:008-KStáhnout
2022-11-30 23:00:008-KStáhnout
2022-11-23 00:00:008-KStáhnout
2022-11-22 23:00:008-KStáhnout
2022-11-14 00:00:008-KStáhnout
2022-11-14 00:00:0010-QStáhnout
2022-11-13 23:00:008-KStáhnout
2022-11-13 23:00:0010-QStáhnout
2022-11-10 00:00:008-KStáhnout
2022-11-09 23:00:008-KStáhnout
2022-11-07 00:00:008-KStáhnout
2022-11-06 23:00:008-KStáhnout
2022-09-28 01:00:008-KStáhnout
2022-09-28 00:00:008-KStáhnout
2022-09-21 01:00:008-KStáhnout
2022-09-21 00:00:008-KStáhnout
2022-08-15 01:00:008-KStáhnout
2022-08-15 01:00:0010-QStáhnout
2022-08-15 00:00:008-KStáhnout
2022-08-15 00:00:0010-QStáhnout
2022-06-28 01:00:008-KStáhnout
2022-06-28 01:00:0010-KStáhnout
2022-06-28 00:00:008-KStáhnout
2022-06-28 00:00:0010-KStáhnout
2022-05-24 01:00:008-KStáhnout
2022-05-24 00:00:008-KStáhnout
2022-03-30 01:00:008-KStáhnout
2022-03-30 00:00:008-KStáhnout
2022-02-28 00:00:008-KStáhnout
2022-02-27 23:00:008-KStáhnout
2022-02-14 00:00:008-KStáhnout
2022-02-14 00:00:0010-QStáhnout
2022-02-13 23:00:008-KStáhnout
2022-02-13 23:00:0010-QStáhnout
2021-11-15 00:00:008-KStáhnout
2021-11-15 00:00:0010-QStáhnout
2021-11-14 23:00:008-KStáhnout
2021-11-14 23:00:0010-QStáhnout
2021-10-01 01:00:008-KStáhnout
2021-10-01 00:00:008-KStáhnout
2021-09-28 01:00:008-KStáhnout
2021-09-28 00:00:008-KStáhnout
2021-09-21 01:00:008-KStáhnout
2021-09-21 01:00:0010-QStáhnout
2021-09-21 00:00:008-KStáhnout
2021-09-21 00:00:0010-QStáhnout
preloader